Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA is a diversified global healthcare conglomerate, operating primarily through Fresenius Medical Care and Fresenius Kabi. This dual structure makes it a dominant force in the apheresis market, specializing in dialysis, hospital management, and comprehensive outpatient medical services globally. Fresenius is a leading provider of dialysis products, including machines and dialyzers, and leverages this expertise in therapeutic apheresis. Their product offerings encompass sophisticated systems like the Prometheus system for liver support and the advanced APRΞD platform, which incorporates cutting-edge software and hardware for enhanced process control and automation during blood component collection. Fresenius is committed to clinical innovation, evident in the launch of devices like the Amicus Extracorporeal Photopheresis (ECP) System. The company’s strategic focus involves expanding its presence in emerging markets and delivering comprehensive, automated healthcare solutions worldwide, catering to both donor and therapeutic procedures.
Latest Market Research Report on Apheresis Download PDF Brochure Now
Terumo BCT, Inc.
Terumo BCT, Inc., a subsidiary of Terumo Corporation, is a recognized global leader in therapeutic apheresis and cell collection technologies. The company is dedicated to advancing apheresis to expand treatment options for patients. Core products include the Spectra Optia Apheresis System, which supports therapeutic plasma exchange, red blood cell exchange, and sophisticated cell collections, and the Trima Accel Automated Blood Collection System. Terumo BCT is heavily invested in the rapidly evolving field of cell therapy technologies, utilizing systems like the Quantum Flex Cell Expansion System, and has engaged in strategic partnerships, such as the collaboration with Santersus AG on the NucleoCapture technology for sepsis treatment. By focusing on integrating high-quality technologies and software throughout the blood supply chain—from collection and processing to pathogen reduction—Terumo BCT ensures blood safety and operational efficiency for blood centers and hospitals globally.
Haemonetics Corporation
Haemonetics Corporation is a pivotal global healthcare corporation known for its innovative solutions and comprehensive suite of apheresis equipment, focusing on advancing patient care while optimizing healthcare cost efficiencies. The company provides advanced, automated apheresis devices to blood donation centers and hospitals for a variety of procedures, including plasmapheresis, plateletpheresis, and leukapheresis. A key offering in their portfolio is the NexSys PCS with Persona technology, designed to customize plasma collection based on an individual donor’s body composition, improving efficiency and donor experience. Haemonetics pursues robust growth strategies, combining organic development with inorganic acquisitions, to expand its market presence and maintain competitiveness. Their specialization in blood management products solidifies their position as a central figure in the apheresis landscape, driving innovation in collection and separation technologies.
Asahi Kasei Medical Co., Ltd.
Asahi Kasei Medical Co., Ltd., a wholly-owned subsidiary of Asahi Kasei Corp., is a significant player in the apheresis market, leveraging its expertise in polymer chemistry, life science, and mechanical engineering to develop innovative medical products. The company focuses on separation technology based on advanced functional materials such as membranes and adsorbents. Its product line encompasses a wide range of therapeutic apheresis products, high-performance dialyzers, and specialized filters for leukocyte and virus removal. Specific apheresis devices manufactured by Asahi Kasei include Plasmaflo OP, Cascadeflo EC, IMMUSORBA TR, IMMUSORBA PH, and CUREFLO, addressing various treatment needs. By combining its technological strengths, Asahi Kasei Medical provides reliable solutions that are essential for bioprocess applications and therapeutic apheresis, constantly expanding its global reach through strategic initiatives like the establishment of affiliates in key markets such as China.
B. Braun Melsungen AG
B. Braun Melsungen AG, known as B. Braun SE, is a long-established German medical and pharmaceutical device company recognized as a leading global provider of integrated healthcare solutions. With a vast product range, B. Braun is deeply engaged in the apheresis market, focusing primarily on therapeutic treatments. The company develops and utilizes various sophisticated machines for apheresis, such as the Plasmat Futura device, specifically designed to perform H.E.L.P. apheresis (heparin-induced extracorporeal LDL precipitation). In conjunction with these devices, B. Braun manufactures associated essential components like specialized filters, absorbers, and bloodline systems, ensuring comprehensive and effective treatment delivery. Operating with a significant global footprint across more than 60 countries, B. Braun reinforces its reputation by providing high-quality, reliable products that streamline complex laboratory and clinical workflows for physicians and patients.
Nikkiso Co., Ltd.
Nikkiso Co., Ltd. is a major Japanese industrial technology manufacturer whose business segments include medical devices, with a growing focus on blood purification and apheresis. Leveraging its original technology and deep know-how, Nikkiso has strategically expanded its presence in the blood purification field, including perioperative and emergency applications. The company provides apheresis solutions for medical treatments like ulcerative colitis. Nikkiso has prioritized global expansion, successfully launching new apheresis products in Europe and Japan, and setting plans for market entry into Asia and the United States in the near future. Furthermore, Nikkiso maintains a dominant market share (over 50%) of dialysis machines in Japan, underscoring its significant technical capabilities and established role in renal and blood-related medical device manufacturing.
Kaneka Corporation
Kaneka Corporation is a diversified Japanese chemicals, food products, and medical devices company that actively contributes to the apheresis market, particularly through its specialized medical devices segment. The company focuses on developing and commercializing therapeutic blood purification technologies. A key example of their commitment to apheresis innovation is the launch of rheocarna, an adsorption type blood purification device specifically designed to treat severe forms of arteriosclerosis obliterans. Kaneka utilizes its broad expertise in materials science to create products that support targeted removal of disease-related elements from the blood. As a key player, Kaneka is continually advancing its technology to address unmet medical needs, participating in the broader market for therapeutic apheresis alongside other global leaders in the medical device and blood management sectors.
Cerus Corporation
Cerus Corporation is a medical device company with a focus on enhancing blood safety, making it a relevant player in the apheresis market, especially concerning blood component management post-collection. While Cerus does not primarily manufacture apheresis equipment, its core mission aligns with the final utilization and safety of blood components collected via apheresis. The company is known for its INTERCEPT Blood System, which is used for pathogen reduction in blood components (platelets and plasma) intended for transfusion. This system is crucial for ensuring the safety and quality of products harvested through apheresis procedures. By addressing the critical need for enhanced blood safety, Cerus plays an essential role in the continuum of care that starts with apheresis collection, supporting blood centers and hospitals globally by mitigating transfusion-transmitted infections and improving the overall quality of transfusable blood products.
Kawasumi Laboratories Inc.
Kawasumi Laboratories Inc., often listed as SB-Kawasumi Laboratories Inc., is a specialized Japanese company recognized for its contributions to the blood management and apheresis market. As a producer of medical devices and supplies, Kawasumi focuses on products related to blood purification, blood transfusion, and dialysis. Their involvement in apheresis centers on the provision of necessary components and systems for these procedures. Kawasumi is one of the important key players in the apheresis market, particularly in Asia-Pacific, contributing essential equipment and consumables used in various therapeutic and donor apheresis procedures. The company’s expertise in manufacturing high-quality disposable medical supplies, including tubing sets and filters, supports the operational consistency and reliability required by blood centers and hospitals performing apheresis treatments.
Latest Market Research Report on Apheresis Download PDF Brochure Now